darunavir/cobicistat

The combination of darunavir and cobicistat is prescribed alongside other medications to treat HIV infection. It is important to note that this combination does not cure or prevent HIV infection or AIDS. HIV is the virus responsible for causing AIDS.

According to the study, darunavir levels decrease by 30% when taken without food. This decrease in drug levels can result in insufficient control of HIV and an increased risk of developing resistance. The study examined the effects of different types of food on darunavir absorption, including a standard breakfast, a high-fat breakfast, a nutritional protein-rich drink, and a croissant with coffee.

This drug may interact with certain products, including orlistat, certain seizure medications (such as carbamazepine, phenytoin, primidone), barbiturates (such as phenobarbital, secobarbital), and a specific combination HIV medication (elvitegravir/cobicistat/emtricitabine/tenofovir).

Darunavir, in combination with a low dose of ritonavir, is an oral nonpeptidic HIV-1 protease inhibitor (PI) that is prescribed as part of an antiretroviral therapy (ART) regimen for both treatment-experienced and treatment-naive patients with HIV-1 infection.

Prezcobix is always prescribed alongside other medications for the treatment of HIV. It is a combination drug that consists of two active ingredients: darunavir and cobicistat.

Darunavir, also known by its brand name Prezista, is a medication that has been approved by the FDA for the treatment of HIV infection in both adults and children.

Bictegravir belongs to a group of drugs known as integrase strand transfer inhibitors (INSTIs), while emtricitabine and tenofovir AF are classified as nucleoside reverse transcriptase inhibitors (NRTIs).

Darunavir, which is also referred to as darunavir ethanolate or DRV and sold under the brand name Prezista, is a medication that is utilized in antiretroviral therapy (ART).

Darunavir, also known by its brand name Prezista, is a medication that has been approved by the FDA for the treatment of HIV infection in both adults and children.

Biktarvy is composed of three distinct medications, namely bictegravir, emtricitabine, and tenofovir alafenamide.

Cobicistat, also known by its brand name Tybost, is a prescription medication that has been approved by the FDA for use in both adults and children. It is typically used in combination with the HIV medications atazanavir (Reyataz) or darunavir (Prezista).

Darunavir belongs to a group of drugs known as protease inhibitors. Its mechanism of action involves reducing the levels of HIV in the bloodstream. While darunavir cannot cure HIV, it can potentially lower the risk of developing AIDS and HIV-related conditions, including severe infections and cancer.

Darunavir, also referred to as TMC114, exhibits strong antiviral effects against HIV-1 strains that are resistant to currently approved protease inhibitors (PIs).

Drug Interaction: Capmatinib and Cobicistat
– When Capmatinib is combined with Cobicistat, the serum concentration of Capmatinib can be increased.

Drug Interaction: Cobicistat and Carbamazepine
– When Cobicistat is combined with Carbamazepine, the metabolism of Cobicistat can be increased.

In April 2021, it was advised that alfusozin, ranolazine, dronedarone, carbamazepine, phenobarbital, phenytoin, rifampicin, lurasidone pimozide, dihydroergotamine, ergotamine, cisapride, lovastatin, simvastatin, triazolam or oral midazolam should not be taken with cobicistat.

COBI is a drug that enhances the pharmacokinetics of antiretroviral drugs. It can be taken alone or as part of a combination product with other drugs.

Cobicistat 150 mg once daily has a similar pharmacokinetic boosting effect as ritonavir 100 mg once daily. However, unlike ritonavir, cobicistat does not induce any enzymes related to CYP450, UGT, or P-gp.

Cobicistat (Tybost®) is a drug that enhances the effects of HIV-1 protease inhibitors (PIs) atazanavir and darunavir in adults by inhibiting cytochrome P450 (CYP) 3A enzymes. It is used as a pharmacokinetic enhancer, or booster, in the EU.

This product is utilized in conjunction with other medications for HIV to effectively manage HIV infection. It aids in reducing the level of HIV in your body, thereby enhancing the functionality of your immune system.

To summarize, compound 3 (cobicistat, GS-9350) is a highly effective and specific inhibitor of human CYP3A, but it does not exhibit significant anti-HIV activity.

Cobicistat is a medication that enhances the effectiveness of specific HIV drugs, serving as an alternative to the booster ritonavir.

Cobicistat selectively inhibits cytochromes P450 of the CYP3A subfamily, which enhances the systemic exposure of CYP3A substrates by inhibiting their metabolism.

On April 21, 2014, the U.S. FDA accepted Gilead Sciences’ New Drug Application for Cobicistat for HIV therapy. Later, on September 25, 2014, the FDA approved Tybost (cobicistat) for use in the treatment of HIV-1 infection.

Prezcobix Prices, Coupons, and Patient Assistance Programs: Prezcobix, a combination antiviral drug containing cobicistat and darunavir, is frequently prescribed for the treatment of HIV infection. The price of Prezcobix oral tablets (150 mg-800 mg) can vary depending on the pharmacy, with an average cost of approximately $2,531 for a 30-tablet supply. However, there are various options available to help patients afford this medication, including coupons and patient assistance programs.

Darunavir has the potential to cause severe and life-threatening side effects, such as liver complications and severe skin reactions or rashes.

Symtuza, which is a combination of cobicistat, darunavir, emtricitabine, and tenofovir alafenamide, belongs to the antiviral combinations drug class. It is frequently prescribed for the treatment of HIV Infection. The price of Symtuza oral tablets (150 mg-800 mg-200 mg-10 mg) can vary depending on the pharmacy you go to, but it is typically around $4,846 for a 30-tablet supply.

A generic drug is a medication that contains the same active ingredient as a brand-name drug, but is usually sold under its chemical name rather than a brand name. Generic drugs are typically produced and sold after the patent for the brand-name drug has expired. They are equivalent in terms of safety, effectiveness, dosage form, strength, and route of administration to the brand-name drug.

On June 3, 2023, Lupin introduced AB-rated generic versions of Janssen’s Prezista (darunavir) tablets in strengths of 600 mg and 800 mg.

Cobicistat functions as a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) isoforms. By inhibiting CYP3A-mediated metabolism, cobicistat enhances the systemic exposure of atazanavir and darunavir, both CYP3A substrates. This ultimately allows for greater anti-viral effectiveness at a reduced dosage.

Input: Darunavir
Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Emtricitabine / tenofovir alafenamide
Dosage Form(s) Available
Oral tablet
Oral tablet
Oral tablet
Brand Names
Prezista
N/A
Descovy

Output:
Darunavir is available in oral tablet form and is sold under the brand name Prezista.
Biktarvy is a combination medication containing bictegravir, emtricitabine, and tenofovir alafenamide. It is available in oral tablet form.
Emtricitabine / tenofovir alafenamide is available in oral tablet form and is sold under the brand name Descovy.

Alternatives to darunavir may include Truvada, Atripla, Norvir, Triumeq, Dovato or Isentress.

Darunavir is advantageous because it maintains its virological activity even when there are multiple protease mutations present. To enhance its bioavailability, it is coadministered with low-dose ritonavir.